Roivant Sciences Ltd.
36.49USD
-0.9600 (-2.56%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ROIV.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.45▼ | -$0.4 | 0 | 3 |
| Next quarter | -$0.41▼ | -$0.37 | 0 | 3 |
| Current year | -$1.58▼ | -$1.5 | 0 | 3 |
| Next year | -$1.72▼ | -$1.56 | 1 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.36 | -$0.34 | +0.02 (+4.9%) |
| 2026-03-31 | -$0.35 | -$0.32 | +0.03 (+9.3%) |
| 2025-12-31 | -$0.31 | -$0.24 | +0.07 (+23.0%) |
| 2025-09-30 | -$0.3 | -$0.28 | +0.03 (+9.3%) |
97 ratings from 17 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Oct 12, 2026 |
| Stifel | Initiated | Buy | $51 | Sep 17, 2026 |
| TD Cowen | Maintained | Buy | $50 $55 | Sep 9, 2026 |
| Guggenheim | Maintained | Buy | $42 $46 | Sep 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $41 $47 | Sep 8, 2026 |
| Jefferies | Maintained | Buy | $42 $52 | Sep 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $41 | Aug 28, 2026 |
| Citigroup | Maintained | Buy | $42 $46 | Aug 10, 2026 |
| Guggenheim | Maintained | Buy | $36 $42 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $34 $41 | Aug 7, 2026 |
| Guggenheim | Maintained | Buy | $30 $36 | May 26, 2026 |
| Citigroup | Maintained | Buy | $35 $42 | May 21, 2026 |
| TD Cowen | Maintained | Buy | $38 $41 | May 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $34 | May 21, 2026 |
| Piper Sandler | Maintained | Overweight | $22 $40 | Apr 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $33 $34 | Mar 4, 2026 |
| Citigroup | Maintained | Buy | $26 $35 | Feb 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $26 $33 | Feb 10, 2026 |
| Guggenheim | Maintained | Buy | $28 $30 | Feb 9, 2026 |
| Leerink Partners | Maintained | Outperform | $29 $32 | Dec 15, 2025 |
| Goldman Sachs | Maintained | Buy | $24 $33 | Dec 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $23 $26 | Dec 12, 2025 |
| Citigroup | Maintained | Buy | $25 $26 | Nov 11, 2025 |
| Citigroup | Maintained | Buy | $16 $25 | Oct 29, 2025 |
| Goldman Sachs | Maintained | Buy | $20 $24 | Sep 18, 2025 |
190 filings from 24 insiders · 17 buy / 16 sell over 6m
Officers and directors of ROIV, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Venker EricOfficer, President & Immunovant CEO | Sell | 14.1k | $35.42 | $501k | Oct 20, 2026 |
| Venker EricOfficer, President & Immunovant CEO | Sell | 185.9k | $35.09 | $6.52M | Oct 20, 2026 |
| Sukhatme MayukhDirector; Officer, President & CIO | Tax | 20.0k | $33.53 | $670k | Oct 16, 2026 |
| Gline MatthewDirector; Officer, CEO | Tax | 34.6k | $33.53 | $1.16M | Oct 16, 2026 |
| Epperly Melissa B,Director | ExerciseStock Option (Right to Buy) | 17.8k | — | — | Oct 1, 2026 |
| Epperly Melissa B,Director | Sell | 900 | $36.57 | $33k | Oct 1, 2026 |
| Epperly Melissa B,Director | Sell | 16.9k | $36.08 | $608k | Oct 1, 2026 |
| Epperly Melissa B,Director | Exercise | 17.8k | $4.46 | $79k | Oct 1, 2026 |
| Sukhatme MayukhDirector; Officer, President & CIO | Tax | 46.9k | $36.57 | $1.71M | Sep 30, 2026 |
| Venker EricOfficer, President & Immunovant CEO | ExerciseStock Option (Right to Buy) | 200.0k | — | — | Sep 30, 2026 |
| Venker EricOfficer, President & Immunovant CEO | Sell | 200.0k | $36.62 | $7.32M | Sep 30, 2026 |
| Venker EricOfficer, President & Immunovant CEO | Exercise | 200.0k | $3.85 | $770k | Sep 30, 2026 |
| Gline MatthewDirector; Officer, CEO | Tax | 76.2k | $36.57 | $2.79M | Sep 30, 2026 |
| Torti FrankOfficer, President and Vant Chair | Tax | 40.3k | $36.57 | $1.47M | Sep 30, 2026 |
| Humes JenniferOfficer, Chief Accounting Officer | Tax | 3.9k | $39.77 | $154k | Sep 20, 2026 |
| Pulik RichardOfficer, CFO | Tax | 2.1k | $39.77 | $85k | Sep 20, 2026 |
| MANCHESTER KEITH SDirector | Grant | 5.1k | — | — | Sep 16, 2026 |
| MANCHESTER KEITH SDirector | GrantStock Option (Right to Buy) | 10.5k | — | — | Sep 16, 2026 |
| MOMTAZEE JAMES CDirector | Grant | 5.1k | — | — | Sep 16, 2026 |
| MOMTAZEE JAMES CDirector | GrantStock Option (Right to Buy) | 10.5k | — | — | Sep 16, 2026 |
No analyst notes on ROIV yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 9 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 10 | 1 | 0 | 0 | Buy1.92 |
| 2 mo ago | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
| 3 mo ago | 2 | 9 | 1 | 0 | 0 | Buy1.92 |
Members whose judged calls on ROIV have played out most reliably.
No settled calls on ROIV yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice